Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Hunting following FES acquisition

(Sharecast News) - Analysts at Berenberg lowered their target price on oil and gas industry suppler Hunting from 480.0p to 465.0p on Tuesday after it acquired Flexible Engineered Solutions £50.0m in cash. The deal has now been completed, and Berenberg moved to include its contribution in its estimates from H225 onwards, noting that the business will increase Hunting's gearing to the "attractive subsea oil and gas market".

Berenberg said the subsea oil and gas market will make up 18% of group revenue on its FY26E estimates and highlighted that margins were accretive to the group. It also said the outlook for future activity levels "remains positive".

"We update our model to include FES's contribution from H225 and adjust our EV estimate for the £50.0m consideration paid from available cash. We expect consensus EBITDA estimates for 2026 to increase by circa 7%," said the German bank, which reiterated its 'buy' rating on the stock.

"We also take the opportunity to adjust our wider group estimates to consider current market conditions, including higher volatility in commodity prices. Our group EBITDA estimates change by -3%, 0% and -2% in 2025E, 2026E and 2027E, respectively."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.